Navigation Links
Pathwork Diagnostics Collaborates With Guy's and St Thomas' on Tissue of Origin Test Validation in the UK
Date:12/9/2008

London Hospitals First in UK to Perform Study Utilizing Pathwork Tissue of Origin Test

SUNNYVALE, Calif., Dec. 9 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced today a collaboration with Guy's and St Thomas' NHS Foundation Trust in London. Guy's and St Thomas' will be the first hospitals in the United Kingdom to conduct a research study on the Pathwork(R) Tissue of Origin Test, which aids in the diagnosis of hard-to-identify tumors.

"We're extremely excited about entering into this partnership with Guy's and St Thomas' NHS Foundation Trust," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "In this study, pathologists and oncologists at Guy's and St Thomas' will not only be able to validate the test for use in their institution, but more importantly, soon be able to use information generated to help them determine the most effective, cancer-specific treatment regimen for hard-to-diagnose cases."

In the collaboration, Dr. Giuseppe Culora, the clinical director, and Dr. Eugene Halligan, the scientific director, are performing a proof-of-concept validation study. "Since patients with cancer of unknown primary have a very poor prognosis, we hope that with this novel diagnostic test our oncologists will have new information at their fingertips to guide treatment and be able to offer a better standard-of-care for our cancer patients," said Dr. Culora.

The Pathwork Tissue of Origin Test uses a microarray to measure the RNA expression pattern, comprising more than 1,500 genes, in the tumor and compares it to expression patterns of a panel of 15 known tumor types, representing 60 morphologies overall, to help determine the tumor's origin. Earlier this year, Pathwork became the first U.S.-based company to receive U.S. Food and Drug Administration (FDA) clearance for a molecular diagnostics test under the FDA's new IVDMIA (In Vitro Diagnostic Multivariate Index Assays) guidelines.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market - the Pathwork(R) Tissue of Origin Test - utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. The test aids in determining a hard-to-identify tumor's origin so that standard-of-care, cancer-specific treatment can begin. The test is FDA-cleared as an in vitro diagnostic kit, while a functionally equivalent version of the test is also available through the CLIA-certified Pathwork(R) Diagnostics Laboratory. For more information, call 1.877.808.0006 or visit www.pathworkdx.com.

About Guy's and St Thomas' NHS Foundation Trust

Guy's and St Thomas' provides around 3/4 million patient contacts in acute and specialist hospital services every year. As one of the biggest NHS Trusts in the UK, it employs over 9,000 staff. The Trust works in partnership with the Schools of Medicine, Dentistry, Nursing and Biomedical Sciences of King's College London and other Higher Education Institutes to deliver high quality education and research. Website: www.guysandstthomas.nhs.uk.

King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are working together to create a world-leading Academic Health Sciences Centre (AHSC). AHSC brings together an unrivalled range and depth of clinical and research expertise, spanning both physical and mental health. The combined strengths will drive improvements in care for patients, allowing them to benefit from breakthroughs in medical science and receive leading edge treatment at the earliest possible opportunity. For more information, visit www.londonsahsc.org.

(C)2008 Pathwork Diagnostics, Inc. All rights reserved. Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics logo are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
2. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
3. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
4. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
5. Hypertension Diagnostics Announces Fiscal Year 2007 Results
6. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
7. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
10. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
11. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: